Jefferies Financial Group Inc. Purchases Shares of 42,777 Incyte Co. (NASDAQ:INCY)

Jefferies Financial Group Inc. bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,777 shares of the biopharmaceutical company's stock, valued at approximately $2,955,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quintet Private Bank Europe S.A. bought a new stake in Incyte during the fourth quarter worth $26,000. Global X Japan Co. Ltd. lifted its stake in shares of Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 230 shares during the last quarter. R Squared Ltd bought a new position in shares of Incyte in the 4th quarter valued at $30,000. Raiffeisen Bank International AG bought a new position in shares of Incyte in the 4th quarter valued at $34,000. Finally, Blue Trust Inc. lifted its stake in shares of Incyte by 124.6% in the 4th quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 329 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on INCY shares. JMP Securities reiterated a "market perform" rating on shares of Incyte in a research note on Tuesday, February 11th. Stifel Nicolaus increased their price target on Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, February 10th. Citigroup dropped their price target on Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research note on Tuesday, February 11th. Morgan Stanley dropped their price target on Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. Finally, Truist Financial increased their price objective on Incyte from $72.00 to $73.00 and gave the company a "hold" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Incyte currently has an average rating of "Hold" and a consensus price target of $73.60.

Incyte Trading Down 1.2%

Incyte stock traded down $0.79 during trading hours on Friday, reaching $65.25. 3,737,618 shares of the company's stock were exchanged, compared to its average volume of 2,289,471. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The firm's 50 day simple moving average is $60.80 and its 200 day simple moving average is $67.43. Incyte Co. has a twelve month low of $53.56 and a twelve month high of $83.95. The firm has a market capitalization of $12.63 billion, a PE ratio of 241.68, a PEG ratio of 0.41 and a beta of 0.68.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $996.17 million. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The business's revenue was up 19.5% compared to the same quarter last year. During the same period last year, the business posted $0.64 EPS. Research analysts predict that Incyte Co. will post 4.86 earnings per share for the current year.

Insider Activity

In other Incyte news, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,809,101.52. The trade was a 2.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the transaction, the executive vice president now owns 33,567 shares of the company's stock, valued at $2,272,150.23. This trade represents a 37.11% decrease in their position. The disclosure for this sale can be found here. 17.80% of the stock is currently owned by company insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.